MedTrace Logo

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

NCT01707537 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-02-20

No results posted yet for this study

Summary

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Conditions

  • Prevention Harmful Effects

Interventions

BIOLOGICAL

Euvichol

1.5mL/vial, 1vial at 2-week intervals twice

Sponsors & Collaborators

  • Instituto Universitario IVI

    collaborator OTHER

  • EuBiologics Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Hong J Hee, Ph.D · Chungnam National University Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • South Korea

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01707537 on ClinicalTrials.gov